 |
|
|
| |
Safety and Efficacy of VRC07-523LS Plus
Long-Acting Cabotegravir in the Phase II ACTG A5357 Trial
|
| |
| |
Babafemi Taiwo, Yu E. Zheng, Katherine Rodriguez, Leah Burke, Jackie Reeves, Paul Wannamaker, Lucio Gama, Christos Petropoulos, Kimberly K. Scarsi, Pablo Belaunzaran-Zamudio, Ronald D’Amico, Katharine J. Bar, Pablo Tebas, for the ACTG A5357 Team
Long-Acting Cabotegravir and VRC-07523LS to Maintain Viral Suppression in Adults with HIV-1
Babafemi O. Taiwo, MD
CROI 2024
March 4, 2024
|
| |
|
|
|
|
|
